Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume Following Analyst Upgrade

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) saw unusually-strong trading volume on Friday after Truist Financial raised their price target on the stock from $13.00 to $18.00. Truist Financial currently has a buy rating on the stock. Approximately 1,016,893 shares traded hands during mid-day trading, an increase of 21% from the previous session’s volume of 837,308 shares. The stock last traded at $3.5350 and had previously closed at $3.46.

Several other research analysts have also weighed in on IVA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Cantor Fitzgerald assumed coverage on Inventiva in a research report on Friday, July 17th. They issued an “overweight” rating on the stock. Guggenheim upped their target price on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. Finally, Piper Sandler restated an “overweight” rating on shares of Inventiva in a research report on Wednesday, September 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $15.86.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP increased its holdings in Inventiva by 155.5% during the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after purchasing an additional 43,280 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Inventiva during the 1st quarter valued at about $1,111,000. Persistent Asset Partners Ltd purchased a new position in Inventiva in the 4th quarter worth approximately $603,000. NEXTBio Capital Management LP bought a new stake in shares of Inventiva in the 4th quarter worth $6,039,000. Finally, Eventide Asset Management LLC purchased a new position in Inventiva in the 4th quarter worth about $1,155,000. 19.06% of the stock is currently owned by hedge funds and other institutional investors.

Inventiva Trading Up 4.2%

The stock’s 50-day moving average is $4.34 and its two-hundred day moving average is $4.67.

Inventiva (NASDAQ:IVA) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.14) EPS for the quarter. The business had revenue of $0.75 million for the quarter. On average, equities analysts expect that Inventiva S.A. Sponsored ADR will post -0.81 EPS for the current year.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.